Pulmonx Co. (NASDAQ:LUNG) General Counsel David Aaron Lehman Sells 22,355 Shares

Pulmonx Co. (NASDAQ:LUNG) General Counsel David Aaron Lehman sold 22,355 shares of the firm’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $7.65, for a total value of $171,015.75. Following the completion of the transaction, the general counsel now owns 175,496 shares in the company, valued at $1,342,544.40. The trade was a 11.30 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Pulmonx Trading Down 5.5 %

Pulmonx stock traded down $0.48 during midday trading on Wednesday, hitting $8.19. 240,321 shares of the stock were exchanged, compared to its average volume of 337,083. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $325.93 million, a price-to-earnings ratio of -5.69 and a beta of 0.64. The stock’s 50-day simple moving average is $6.89 and its 200 day simple moving average is $6.92. Pulmonx Co. has a fifty-two week low of $5.46 and a fifty-two week high of $10.01.

Pulmonx (NASDAQ:LUNG) last announced its quarterly earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. The business had revenue of $23.77 million during the quarter, compared to the consensus estimate of $22.29 million. On average, equities analysts anticipate that Pulmonx Co. will post -1.55 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on LUNG. Citigroup reiterated a “neutral” rating and issued a $7.50 target price (down from $17.00) on shares of Pulmonx in a research report on Wednesday, December 11th. Wells Fargo & Company lowered their target price on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Pulmonx has a consensus rating of “Moderate Buy” and a consensus target price of $12.75.

Hedge Funds Weigh In On Pulmonx

Several large investors have recently modified their holdings of LUNG. FMR LLC raised its holdings in Pulmonx by 11.2% in the 3rd quarter. FMR LLC now owns 5,872,882 shares of the company’s stock valued at $48,686,000 after buying an additional 591,859 shares during the period. Deerfield Management Company L.P. Series C acquired a new stake in shares of Pulmonx during the fourth quarter valued at about $10,421,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Pulmonx by 5.2% in the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company’s stock valued at $9,238,000 after acquiring an additional 55,279 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Pulmonx by 2.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,055,522 shares of the company’s stock worth $8,750,000 after acquiring an additional 25,002 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Pulmonx by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 902,240 shares of the company’s stock worth $6,128,000 after acquiring an additional 9,454 shares during the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.